Association between presence of the metabolic syndrome and its components with carotid intima-media thickness and carotid and femoral plaque area: a population study

Diabetology & Metabolic Syndrome

Andrew N Nicolaides³  Dawn Bond⁴  Niki Georgiou²  Theodosis Tyllis²  Panayiotis Kouis¹  Maura Griffin⁴  Andrie G Panayiotou⁵ 

[1] Cyprus International Institute for Environmental and Public Health in association with Harvard School of Public Health, Cyprus University of Technology, P.O. Box: 50329, Limassol, Cyprus;Vascular Screening and Diagnostic Centre, 2 Kyriacou Matsi, Nicosia 2368, Cyprus;Department of Vascular Surgery, Imperial College, London SW72BX, UK;Vascular Noninvasive Screening and Diagnostic Centre, 30 Weymouth street, W1G 7BS, London, UK;The Cyprus Cardiovascular Disease Educational and Research Trust, 2 Kyriacou Matsi, Nicosia 2368, Cyprus

关键词: IMT;    Carotid;    Femoral;    Plaque area;    Atherosclerotic plaques;    Metabolic syndrome components;    Metabolic syndrome;   

Others  :  821638
DOI  :  10.1186/1758-5996-5-44

 received in 2013-06-20, accepted in 2013-08-08,  发布年份 2013

【 摘 要 】

Background

We aimed to explore the association between presence and number of components of the Metabolic Syndrome (MetS) and subclinical atherosclerosis outcomes (common carotid intima media thickness, plaque presence and sum of plaque area) in both the carotid and femoral bifurcations.

Methods

Cross-sectional analysis of 771 volunteers from the ongoing epidemiological Cyprus Study (46% male; mean age = 60.1 ± 9.8). (a) Carotid intima-media thickness (IMTcc), (b) sum of plaque area in the carotid bifurcations (sum of the largest plaques in each carotid bifurcation-SPAcar), (c) sum of plaque area in the femoral bifurcations (sum of the largest plaques in each femoral bifurcation-SPAfem) and (d) sum of plaque area in both carotid and femoral bifurcations (sum of the areas of the largest plaques present in each of the four bifurcations-SPA) were measured at baseline using ultrasound. Presence and number of components of the MetS was ascertained using the National Cholesterol Education Program ATPIII definition and their association tested using multivariable regression models.

Results

MetS was present in 259 (33.6%) individuals and was associated with a 0.02 mm increase in IMTcc (95% CI: 0.00 to 0.04, p = 0.047) after adjustment for age, sex, family history of CVD, alcohol consumption (BU/week) and smoking (pack-years). Each additional component of the MetS was associated with a 16% higher SPA (95% CI: 6.8% to 25.2%, p_{for trend} = 0.001), a 10% higher SPAcar (95% CI: 5% to 24%, p_{for trend} = 0.003) and a 14% higher SPAfem in the adjusted model.

Conclusions

We confirm an association between the MetS and IMTcc as well as report for the first time an association between the MetS and its components and femoral plaque area, in a general population over 40 years of age. Having any risk factors for the MetS increases the risk for subclinical atherosclerosis, with the risk increasing with each additional component. Using the dichotomous definition of the MetS may be overlooking the risk for subclinical atherosclerosis –and by inference future cardiovascular events- associated with having less than 3 risk factors.

【 授权许可】

   
2013 Panayiotou et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28(4):629-636.
• [2]Alberti K, Zimmet P, Shaw J: Metabolic syndrome—a new world‒wide definition. A consensus statement from the international diabetes federation. Diabetic Med 2006, 23(5):469-480.
• [3]Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J, James WPT, Loria CM, Smith SC: Harmonizing the metabolic syndrome a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
• [4]Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ: The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med 2010, 170(5):478.
• [5]Tzou WS, Douglas PS, Srinivasan SR, Bond MG, Tang R, Chen W, Berenson GS, Stein JH: Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 2005, 46(3):457-463.
• [6]Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56(14):1113-1132.
• [7]Smith SR: Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk. Obesity 2012, 14(S6):128S-134S.
• [8]Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49(4):403-414.
• [9]Malik S, Wong ND, Franklin SS, Kamath TV, Gilbert J, Pio JR, Williams GR: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110(10):1245-1250.
• [10]Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 1997, 146(6):483-494.
• [11]Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M: Prediction of clinical cardiovascular events with carotid intima-media thickness. Circulation 2007, 115(4):459-467.
• [12]Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 96(5):1432-1437.
• [13]Spence JD, Rundek T: Toward clinical applications of carotid ultrasound: intima-media thickness, plaque area, and three-dimensional phenotypes. In Ultrasound and Carotid Bifurcation Atherosclerosis. London: Springer; 2012:431-448.
• [14]Spence JD: Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002, 89(4):10-15.
• [15]Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T: Carotid plaque area a tool for targeting and evaluating vascular preventive therapy. Stroke 2002, 33(12):2916-2922.
• [16]Griffin M, Nicolaides A, Tyllis T, Georgiou N, Martin RM, Bond D, Panayiotou A, Tziakouri C, Doré CJ, Fessas C: Carotid and femoral arterial wall changes and the prevalence of clinical cardiovascular disease. Vasc Med 2009, 14(3):227-232.
• [17]Schmidt C, Fagerberg B, Hulthe J: Non-stenotic echolucent ultrasound-assessed femoral artery plaques are predictive for future cardiovascular events in middle-aged men. Atherosclerosis 2005, 181(1):125.
• [18]Held C, Hjemdahl P, Eriksson S, Björkander I, Forslund L, Rehnqvist N: Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001, 22(1):62-72.
• [19]Vaudo G, Marchesi S, Siepi D, Brozzetti M, Mannarino MR, Pirro M, Schillaci G, Ciuffetti G, Lupattelli G, Mannarino E: Metabolic syndrome and preclinical atherosclerosis: focus on femoral arteries. Metab Clin Exp 2007, 56(4):541-546.
• [20]Pollex RL, Al-Shali KZ, House AA, Spence JD, Fenster A, Mamakeesick M, Zinman B, Harris SB, Hanley AJ, Hegele RA: Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovasc Ultrasound 2006, 4:28. BioMed Central Full Text
• [21]Hassinen M, Komulainen P, Lakka TA, Vaisanen SB, Haapala I, Gylling H, Alen M, Schmidt-Trucksass A, Nissinen A, Rauramaa R: Metabolic syndrome and the progression of carotid intima-media thickness in elderly women. Arch Intern Med 2006, 166(4):444.
• [22]Rundek T, White H, Boden‒Albala B, Jin Z, Elkind MS, Sacco RL: The metabolic syndrome and subclinical carotid atherosclerosis: the Northern Manhattan Study. Journal of the cardiometabolic syndrome 2007, 2(1):24-29.
• [23]Panayiotou A, Nicolaides A, Griffin M, Tyllis T, Georgiou N, Bond D, Martin R, Hoppensteadt D, Fareed J, Humphries S: Leukocyte telomere length is associated with measures of subclinical atherosclerosis. Atherosclerosis 2010, 211(1):176-181.
• [24]Cena H, Tesone A, Niniano R, Cerveri I, Roggi C, Turconi G: Prevalence rate of Metabolic Syndrome in a group of light and heavy smokers. Diabetology & metabolic syndrome 2013, 5(1):28. BioMed Central Full Text
• [25]Ogbera AO: Prevalence and gender distribution of the metabolic syndrome. Diabetol Metab Syndr 2010, 2(1):4. BioMed Central Full Text
• [26]Fujita N, Takei Y: Alcohol consumption and metabolic syndrome. Hepatology Research 2011, 41(4):287-295.
• [27]Empana J, Zureik M, Gariepy J, Courbon D, Dartigues JF, Ritchie K, Tzourio C, Alperovitch A, Ducimetiere P: The metabolic syndrome and the carotid artery structure in noninstitutionalized elderly subjects the three-city study. Stroke 2007, 38(3):893-899.
• [28]Ahluwalia N, Drouet L, Ruidavets J, Perret B, Amar J, Boccalon H, Hanaire-Broutin H, Ferrieres J: Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 2006, 186(2):345-353.
• [29]Adolphe A, Cook LS, Huang X: A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. Mayo Clin Proc 2009, 84(3):221-228.
• [30]Fadini GP, Coracina A, Inchiostro S, Tiengo A, Avogaro A, De Kreutzenberg SV: A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than-additive. Eur J Cardiovasc Prev Rehabil 2008, 15(2):190-196.
• [31]Xu L, Jiang CQ, Lam TH, Lin JM, Yue XJ, Cheng KK, Liu B, Jin YL, Zhang WS, Thomas GN: The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin resistance: the Guangzhou Biobank Cohort study-CVD. Clin Endocrinol (Oxf) 2010, 73(2):181-188.
• [32]Herder M, Arntzen KA, Johnsen SH, Mathiesen EB: The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromso study. Cardiovasc Diabetol 2012, 11(1):77. BioMed Central Full Text
• [33]Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Azen SP: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128(4):262-269.
• [34]Lin H, Liu C, Liao Y, Lin R, Chen C, Juo SH: The risk of the metabolic syndrome on carotid thickness and stiffness: sex and age specific effects. Atherosclerosis 2010, 210(1):155-159.
• [35]Iglseder B, Cip P, Malaimare L, Ladurner G, Paulweber B: The metabolic syndrome is a stronger risk factor for early carotid atherosclerosis in women than in men. Stroke 2005, 36(6):1212-1217.
• [36]Matoba Y, Inoguchi T, Suzuki S, Nasu S, Hashimoto T, Yanase T, Nawata H, Takayanagi R: Impact of metabolic syndrome on the progression of intima-media thickening in Japanese—a follow-up study. Diabetes Res Clin Pract 2009, 86(3):e50-e53.
• [37]Ershova AI, Balakhonova TV, Meshkov AN, Rozhkova TA, Boytsov SA: Ultrasound markers that describe plaques are more sensitive than mean intima-media thickness in patients with familial hypercholesterolemia. Ultrasound Med Biol 2012, 38(3):417-422.
• [38]Spence JD, Hackam DG: Treating arteries instead of risk factors a paradigm change in management of atherosclerosis. Stroke 2010, 41(6):1193-1199.
• [39]Mathiesen EB, Johnsen SH, Wilsgaard T, Bønaa KH, Løchen M, Njølstad I: Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke a 10-year follow-Up of 6584 men and women: the Tromsø study. Stroke 2011, 42(4):972-978.
• [40]Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Løchen M, Njølstad I, Arnesen E: Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men a 6-year follow-up study of 6226 persons: the Tromsø study. Stroke 2007, 38(11):2873-2880.
• [41]Inaba Y, Chen JA, Bergmann SR: Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012, 220(1):128-133.
• [42]Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E: Artery-related differences in atherosclerosis expression implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007, 38(10):2698-2705.
• [43]Kröger K, Kucharczik A, Hirche H, Rudofsky G: Atherosclerotic lesions are more frequent in femoral arteries than in carotid arteries independent of increasing number of risk factors. Angiology 1999, 50(8):649-654.
• [44]Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D, Bekaert S, Blaton V, De Backer GG, Gillebert TC: Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55 years the Asklepios Study. Arterioscler Thromb Vasc Biol 2008, 28(8):1563-1568.
• [45]Nakanishi N, Takatorige T, Fukuda H, Shirai K, Li W, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K: Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004, 64(1):59.
• [46]Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112(20):3066-3072.
• [47]Azevedo A, Bettencourt P, Almeida PB, Santos AC, Abreu-Lima C, Hense H, Barros H: Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities–cross-sectional study of the general population. BMC cardiovascular disorders 2007, 7(1):17. BioMed Central Full Text
• [48]Woodward M, Tunstall-Pedoe H: The metabolic syndrome is not a sensible tool for predicting the risk of coronary heart disease. European Journal of Cardiovascular Prevention & Rehabilitation 2009, 16(2):210-214.
• [49]Sone H, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ito H, Ohashi Y: Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS). J Atheroscler Thromb 2009, 16:380-387.
• [50]Rachas A, Raffaitin C, Barberger-Gateau P, Helmer C, Ritchie K, Tzourio C, Amouyel P, Ducimetière P, Empana J: Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The three-City (3C) Study. Heart 2012, 98(8):650-655.
• [51]Sun D, Wang J, Jiang B, Li L, Li L, Wu L, Wu H, He Y: Metabolic syndrome vs. its components for prediction of cardiovascular mortality: a cohort study in Chinese elderly adults. Journal of Geriatric Cardiology 2012, 9(2):123.
• [52]Reaven GM: The metabolic syndrome: time to get off the merry-go-round? J Intern Med 2011, 269(2):127-136.
• [53]National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults – The evidence report. Obes Res 1998, 6(Suppl. 2):XI-209S.